PDI-IN-4

PDI-IN-4 (compound 14d) (0.48-7.10 μM; 1 h) potently inhibits recombinant human PDI with an IC₅₀ of 0.48 μM, and shows selective inhibition over PDIA3 and PDIA6 isoforms^[1].
PDI-IN-4 (40 μM; 1 h) exhibits a reversible covalent binding mode with recombinant human PDI^[1].
PDI-IN-4 (2-50 μM; 3 min) dose-dependently inhibits U46619-, collagen-, and thrombin-induced aggregation of washed human platelets with IC₅₀ values of 3.5 μM, 13.0 μM, and 25.5 μM, respectively^[1].
PDI-IN-4 (5 μM; 3 min) abolishes U46619-induced GPIIb/IIIa activation and reduces P-selectin expression by 52% in washed human platelets^[1].
PDI-IN-4 (5 μM; 10 min) reduces thrombus formation by 36% in human whole blood perfused through collagen-coated flow chambers at an arterial shear rate of 1500 s^−1[1].
PDI-IN-4 (5-40 μM; 24 h) shows no significant cytotoxicity toward HUVECs, A549, MDA-MB-231, or HepG2 cells at concentrations between 5 and 40 μM after 24 h of incubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.